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Abstract
Background
Although cytogenetics-based prognostication systems are well described in acute myeloid
leukemia (AML), overall survival (OS) remains highly variable within risk groups. An inte-
grated genetic prognostic (IGP) model using cytogenetics plus mutations in nine genes was
recently proposed for patients60 years to improve classification. This model has not been
validated in clinical practice.
Methods and Findings
We retrospectively studied 197 patients with newly diagnosed de novo AML. We compared
OS curves among the mutational profiles defined by the IGP model. The IGP model
assigned patients with intermediate cytogenetics as having favorable, intermediate or unfa-
vorable mutational profiles. The IGP model reassigned 50 of 137 patients with intermediate
cytogenetics to favorable or unfavorable mutational profiles. Median OS was 2.8 years
among 14 patients with intermediate cytogenetics and favorable mutational profiles (mutant
NPM1 and mutant IDH1 or IDH2) and 1.3 years among patients with intermediate muta-
tional profiles. Among patients with intermediate cytogenetics labeled as having unfavor-
able mutational profiles, median OS was 0.8 years among 24 patients with FLT3-ITD
positive AML and high-risk genetic changes (trisomy 8, TET2 and/or DNMT3A) and 1.7
years among 12 patients with FLT3-ITD negative AML and high-risk mutations (TET2,
ASXL1 and/or PHF6). OS for patients with intermediate cytogenetics and favorable
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mutational profiles was similar to OS for patients with favorable cytogenetics (p = 0.697)
and different from patients with intermediate cytogenetics and intermediate mutational pro-
files (p = 0.028). OS among patients with FLT3-ITD positive AML and high-risk genetic
changes was similar to patients with unfavorable cytogenetics (p = 0.793) and different from
patients with intermediate IGP profile (p = 0.022). Patients with FLT3-ITD negative AML and
high-risk mutations, defined as ‘unfavorable’ in the IGP model, had OS similar to patients
with intermediate IGP profile (p = 0.919).
Conclusions
The IGP model was not completely validated in our cohort. However, mutations in six out of
the nine genes can be used to characterize survival (NPMI, IDH1, IDH2, FLT3-ITD, TET2,
DNMT3A) and allow for more robust prognostication in the patients who are re-categorized
by the IGP model. These mutations should be incorporated into clinical testing for younger
patients outside of clinical trials, in order to guide therapy.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease with a wide range of clinical out-
comes. Clinicians have traditionally relied on clinical features of the patient and disease, as well
as the pre-treatment karyotype of leukemic blasts, to predict a patient’s clinical outcome [1,2].
While the presence of a favorable- or unfavorable-risk karyotype may provide useful prognos-
tic information, the outcomes of patients with intermediate cytogenetics—the largest subgroup
—remain highly heterogeneous, making treatment planning challenging. Recently, the prog-
nostic relevance of mutations in FLT3, NPM1 and CEBPA have been established in patients
aged60 years old, specifically in those with intermediate cytogenetic risk [3–6]. These muta-
tions have been incorporated into AML prognostic schemas and are recommended for stan-
dard testing in patients with newly diagnosed AML [7–9]. Despite these advances, our ability
to predict clinical outcomes in patients with AML, especially those with intermediate-risk cyto-
genetics, remains limited [2,3,8].
In recent years, advances in sequencing technology have led to the rapid identification of
additional recurrent somatic mutations in AML. Mutations in several genes, including TET2,
DNMT3A, ASXL1 and PHF6, have been associated with poor prognosis in some cohorts [10–
15], while the prognostic impact of mutations in other genes, such as IDH1 and IDH2, is less
clear [16]. In 2012, Patel et al. proposed a prognostic model that integrates cytogenetics and
mutational status for nine genes [14]. This model was developed using data from patients
enrolled in a multicenter Eastern Cooperative Oncology Group (ECOG) trial of different doses
of anthracycline. Despite the use of this prognostic model by some, its validity in clinical prac-
tice has not been demonstrated. The aim of this study was to evaluate the performance of Patel
et al.’s integrated prognostic model in a cohort of patients with de novo AML seen in clinical
practice, and to investigate refinements that could improve risk prediction.
Methods
Patient cohort
This retrospective study included 197 patients with de novo AML aged60 years who were
treated with intensive induction chemotherapy at the University of Pennsylvania (Penn) or
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Washington University between 2001 and 2013. De novo AML was defined as no prior diagno-
sis of hematologic malignancy or myelodysplastic syndrome, or history of previous chemother-
apy or radiation. The 106 patients from Penn provided written informed consent to donation
of a diagnostic bone marrow, peripheral blood, or pheresis sample to the institution’s Hemato-
logic Malignancies Tissue Bank. Information about patient and disease characteristics, treat-
ment, and clinical outcome was obtained from review of the medical records. We note that 32
of the Penn patients were included in the ECOG 1900 study, which was used by Patel et al. to
develop their integrated model. The 91 patients fromWashington University were identified
from The Cancer Genome Atlas (TCGA), which includes data on clinical and disease charac-
teristics, as well as patient outcomes [17]. Patients with karyotype t(15;17), unknown cyto-
genetic risk, or unavailable clinical information were excluded. All patients received induction
chemotherapy at their respective institutions with cytarabine and an anthracycline [18].
Patients did not all get the same dose of induction chemotherapy, reflecting management dif-
ferences seen in clinical practice at the time patients were treated. Post-induction chemother-
apy and allogeneic stem cell transplant (SCT) regimens were varied and provided at
physicians’ discretion. Overall survival (OS) was the primary endpoint and was defined as the
time between AML diagnosis and death. Patients alive at the time of data collection were cen-
sored at the date of last follow-up. The Penn institutional review board approved this study.
Genetic analysis
Cytogenetic risk was classified as favorable, intermediate, or unfavorable according to the mod-
ified Medical Research Council (MRC) criteria [2]. Mutational analysis of samples from Penn
was performed by the Center for Personalized Diagnostics, using an amplicon-based custom
targeted next-generation sequencing panel for 33 hematologic malignancy-associated genes
(TruSeq Custom Amplicon, Illumina Inc.; S1 Table). The libraries generated were pooled and
sequenced on the Illumina MiSeq (Illumina, Inc.). The mean depth of coverage across the
entire panel was 2000x to achieve a minimum read depth of 250x at any given position. Variant
allele frequency was consistently detectable down to 4%. All of the genes included in the panel
used by Patel et al., except forMLL-PTD and CEBPA, were included in the Penn multiplex
panel. The CEBPA gene was isolated using long range PCR, prepared for sequencing using the
Nextera library preparation kit (Illumina, Inc.), and sequenced in tandem with the hematologic
next-generation sequencing panel (manuscript in preparation). At Washington University,
whole-genome or whole-exome sequencing was performed on all samples with matched nor-
mal skin samples, as previously described [17]. Validation re-sequencing for all of the TCGA
samples was performed at Wash U. The minimum variant allele frequency for single nucleotide
variants was 8%, which was the standard value when using VarScan2 at the time (except for
CEBPA, which was 5%, because coverage was lower for that locus).
Statistical analysis
Differences in dichotomous variables between groups were compared using Pearson’s chi-
square statistic or Fisher’s exact test; differences in continuous variables between groups were
compared using the median score test. Kaplan-Meier OS curves were computed and compared
using the log-rank statistic. Adjusted p-values were computed using Sidak’s procedure for pair-
wise comparisons after a significant log-rank test when there were more than two groups. A
classification model was considered to be valid if there was a significant difference between the
OS curves of each risk group defined by the model. Unadjusted and adjusted hazard ratios
(HR) were estimated using univariate and multivariate Cox proportional hazards regression
models. The reduced multivariate model was developed by backward sequential elimination of
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the least non-significant factor in the model to develop the most parsimonious model. SAS ver-
sion 9.4 was used for statistical analysis. R was used to produce graphs.
Results
Patient characteristics
Patient and disease characteristics, including mutational profile, were similar for the Penn and
TCGA cohorts, with the exception of hemoglobin, peripheral blast percentage and bone marrow
blast percentage (Tables 1 and 2). Among patients at Penn, median follow-up time was 5.1 years
for those alive at the end of the study and 1.3 years for those who died. Among patients at Wash-
ington University, median follow-up was 2.1 years for those alive at the end of the study and 1.0
year for those who died. The two cohorts were combined for further analysis. The median age of
the overall study cohort was 49 years (range, 18–60 years) and 55% were male. The majority
had intermediate cytogenetics (70%) and the three most frequent mutations were NPM1 (34%),
DNMT3A (30%) and FLT3-ITD (26%). Median follow-up time for the study cohort was 3.0
years among patients alive at the end of the study and 1.0 year among patients who died.
Overall, the characteristics of the study cohort, including mutational profile, were similar to
the characteristics of the ECOG 1900 cohort that Patel et al. used to develop their model [14].
Median survival time in the ECOG 1900 cohort, defined by Patel et al. as time to death for
those who died or time to last follow-up for those alive at the time of analysis, was 1.7 years at
the time of reporting [14].
Overall survival by cytogenetic risk
As expected, OS curves varied by cytogenetic risk. OS for patients with favorable cytogenetics
was significantly better than OS for patients with unfavorable cytogenetics (adjusted p = 0.003;
Table 1. Clinical characteristics.
Penn (n = 106) TCGA (n = 91) Penn vs. TCGA Penn + TCGA (n = 197)
Clinical characteristics % % P % (95% CI)
Male 57 53 0.67 55 (48–62)
Race 0.81
White 76 90 82 (76–87)
Nonwhite 9 9 9 (5–14)
Unknown 16 1 9 (6–14)
Cytogenetic proﬁle (MRC) 0.91
Favorable 15 13 14 (9–19)
Intermediate 70 69 70 (63–76)
Unfavorable 15 18 16 (11–21)
Transplant 55 68 0.06 61 (54–68)
Clinical characteristics Median (range) Median (range) P Median (range)
Age at diagnosis 50 (18–60) 47 (18–60) 0.27 49 (18–60)
WBC, x109/L 33 (1–305) 22 (1–298) 0.13 29 (1–305)
Hemoglobin, g/dL 8.8 (3–13) 9.0 (6–13) 0.01 9.0 (3–13)
Platelets, g/dl 50 (6–613) 56 (9–351) 0.70 52 (6–613)
Peripheral blasts, % 50 (0–96) 72 (0–100) <0.01 62 (0–100)
Bone marrow blasts, % 82 (19–100) 72 (0–97) 0.02 77 (0–100)
Penn: Hospital of the University of Pennsylvania; TCGA: The Cancer Genome Network; 95% CI: 95% conﬁdence interval; MRC: Modiﬁed Medical
Research Council; WBC: white blood cell count.
doi:10.1371/journal.pone.0153016.t001
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S1 Fig). Of note, there was no significant difference in OS curves between patients with favor-
able and intermediate cytogenetics (adjusted p = 0.141), or between patients with intermediate
and unfavorable cytogenetics (adjusted p = 0.976).
Overall survival by integrated genetic prognostic profile
The integrated genetic prognostic model developed by Patel et al., (hereafter referred to as the
IGP model; Table 3) was evaluated to determine whether the risk groups it defined had differ-
ent OS in our study cohort. The IGP model reassigned 14 patients with intermediate cytogenet-
ics to the favorable risk group and 36 to the unfavorable risk group, with the remaining 87
patients classified as having intermediate IGP risk. After reclassification, 21% (42), 44% (87),
and 35% (68) of the study patients were categorized as having favorable, intermediate and
unfavorable IGP risk, respectively (Table 3). The OS curves for the three IGP risk groups are
presented in Fig 1. OS in the favorable IGP risk group was significantly better than OS in the
unfavorable IGP risk group (adjusted p<0.001), but there was no significant difference in OS
between patients with favorable and intermediate IGP risk (adjusted p = 0.055), or between
patients with unfavorable and intermediate IGP risk (adjusted p = 0.596).
Survival among subgroups of patients who were reclassified in the IGP model was further
examined in order to better understand the impact of molecularly defined genetic mutations
on prognosis (Fig 2). Fig 2A presents the OS curves for the six cytogenetic and mutational pro-
files that comprise the IGP model and is shown as a summary for comparison of all groups.
Reclassification of a subgroup of patients was considered to be successful when the OS curve of
the reclassified subgroup was 1) similar to the OS curve of the risk group to which it was
Table 2. Genetic characteristics.
Mutational frequency Penn (n = 106) TCGA (n = 91) Penn vs. TCGA Penn + TCGA (n = 197)
% % P % (95% CI)
NPM1 34 34 1.00 34 (27–41)
DNMT3A 33 27 0.44 30 (24–37)
FLT3 0.15
FLT3-ITD 34 18 — 26 (20–33)
FLT3-TKD 5 10 — 7 (4–11)
FLT3 othera 1 1 — 1 (0–4)
FLT3 totalb 39 29 — 34 (27–41)
TET2 9 8 0.80 9 (5–13)
IDH1 9 13 0.50 11 (7–16)
CEBPA 8 11 0.46 9 (5–13)
RUNX1 8 5 0.77 7 (3–10)
IDH2 9 4 0.27 7 (4–11)
ASXL1 4 1 0.38 3 (1–5)
WT1 5 9 0.27 7 (3–10)
TP53 5 4 1.00 5 (2–7)
KIT 4 5 1.00 5 (2–8)
PHF6 0 4 0.42 3 (1–5)
Penn: Hospital of the University of Pennsylvania; TCGA: The Cancer Genome Network.
a
‘FLT3 other’ includes all FLT3 mutations in our database that were not categorized as FLT3-ITD or FLT3-TKD (N841K, D839G, M578T).
b
‘FLT3 total’ includes all FLT3 mutations
doi:10.1371/journal.pone.0153016.t002
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reclassified, and 2) different from the OS curve of the group from which it was removed, i.e. the
intermediate IGP risk group. These subgroups were analyzed in more detail, as discussed
below.
Favorable mutational profile: NPM1 mutant plus IDH1/IDH2 mutant. The OS curve
for patients in the study cohort who had intermediate cytogenetics and mutant NPM1 plus
mutant IDH1 or IDH2 (NPM1mut/IDHmut) was similar to the OS curve for patients with
favorable cytogenetics (adjusted p = 0.697) and was significantly different from the OS curve
for patients in the intermediate IGP risk group (adjusted p = 0.028; Fig 2B). Closer examination
shows that while the OS curve for patients with NPM1mut/IDHmut was similar to the OS
curve for patients with favorable cytogenetics in the first two years, it was closer to the OS
curve for the intermediate IGP risk group after two years. Nine of the 14 patients in this group
relapsed, up to three years after the initial diagnosis.
Unfavorable mutational profiles. Two subgroups of patients with intermediate cytoge-
netics were reclassified to the unfavorable IGP risk group. The OS curve for the 12 patients in
the first subgroup–FLT3-ITD negative AML with co-occurring high-risk mutations as defined
by the IGP model (TET2, ASXL1 and/or PHF6)–was not significantly different from the OS
curves for patients with unfavorable cytogenetics or patients with intermediate IGP risk
(adjusted p = 0.111 and p = 0.919, respectively; Fig 2C). In contrast, the OS curve for the 24
patients in the second subgroup–FLT3-ITD positive AML with co-occurring high-risk genetic
changes (trisomy 8, TET2 and/or DNMT3A)–was similar to the OS curve for patients with
unfavorable cytogenetics (adjusted p = 0.793) and significantly different from the OS curve for
the intermediate IGP risk group (adjusted p = 0.022; Fig 2D).
Modified IGP model
Based on these observations, a modified IGP (M-IGP) model was developed (Table 3, far right
column). The 14 patients with intermediate cytogenetics and favorable mutational profiles
were reclassified as having favorable prognosis. The 24 patients with intermediate cytogenetics
Table 3. Schematic representation of integrated genetic prognostic (IGP) model andmodified IGPmodel.
Cytogenetic
classiﬁcation (n, %)
Mutational proﬁle Integrated genetic prognostic
(IGP) model
Modiﬁed IGP model
(n, %)
CEBPA FLT3-
ITD
Other mutations Subgroup
(n, %)
Proﬁle (n, %)
Favorable (28, 14%) Any 28 (14%) Favorable (42,
21%)
Favorable (42, 21%)
Negative Negative NPM1+ and IDH1/IDH2+ 14 (7%)
Negative Negative MLL-PTD-, TET2-, ASXL1-and
PHF6-
Positive Any Any 87 (44%) Intermediate (87,
44%)
Intermediate (137, 70%) Negative Positive Trisomy 8-, MLL-PTD-, TET2- and
DNMT3A-
Intermediate (99,
50%)
Negative Negative MLL-PTD+, TET2+, ASXL1+ and/
or PHF6+
12 (6%)
Negative Positive Trisomy 8, MLL-PTD+, TET2+ and/
or DNMT3A+
24 (12%) Unfavorable (68,
35%)
Unfavorable (56, 28%)
Unfavorable (32, 16%) Any 32 (16%)
Adapted from Patel et al.[14] “+” = abnormality or mutation present; “-” = abnormality or mutation absent.
doi:10.1371/journal.pone.0153016.t003
Modified Prognostic Model in Younger Patients with AML
PLOSONE | DOI:10.1371/journal.pone.0153016 April 6, 2016 6 / 15
who were FLT3-ITD positive and had co-occurring high-risk mutations (12% of total; 18% of
those with intermediate cytogenetics) were reclassified as having unfavorable prognosis. Over-
all, 21% (42), 50% (99) and 28% (56) of the study patients were categorized as having favorable,
intermediate and unfavorable M-IGP risk, respectively (Table 3). Using this model, the OS
curves were significantly different between patients with favorable and unfavorable M-IGP
profiles (adjusted p<0.001), but there was again no significant difference in OS between
patients with favorable and intermediate M-IGP profiles (adjusted p = 0.178) or between
patients with unfavorable and intermediate M-IGP profiles (adjusted p = 0.100).
Three-year OS rates were 69%, 36% and 16% among patients with favorable, intermediate
and unfavorable M-IGP profiles, respectively (Table 4 and Fig 3). The absolute difference in
three-year OS rates between favorable and unfavorable profiles in the study cohort was larger
in the M-IGP model (53%) than in the IGP (46%) model, but this difference was largest in the
cytogenetic model (56%).
Fig 1. Overall survival by integrated genetic prognostic (IGP) profile (n = 197). The overall survival curve
for patients with favorable IGP risk was significantly different from the curve for patients with unfavorable IGP
risk (adjusted p<0.001). There was no significant difference in survival curves between patients with
favorable IGP risk and patients with intermediate IGP risk (adjusted p = 0.055), or between patients with
unfavorable IGP risk and patients with intermediate IGP risk (adjusted p = 0.596).
doi:10.1371/journal.pone.0153016.g001
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Fig 2. Overall survival in IGPmodel subgroups. A. Overall survival by cytogenetics and mutational profiles. Among patients with intermediate
cytogenetics, three-year overall survival was 59% for those with favorable mutational profiles (A), 33% for those with intermediate mutational profiles (B),
51% for those who were FLT3-ITD negative with high-risk mutations (C) and 11% for those who were FLT3-ITD positive with high-risk mutations (D). Three-
year overall survival was 77% among patients with favorable cytogenetics (favorable) and 21% among patients with unfavorable cytogenetics (unfavorable).
B. Overall survival among patients with favorable mutational profiles. The overall survival curve for patients with intermediate cytogenetics and mutant NPM1
plus mutant IDH1 or IDH2was similar to the survival curve for patients with favorable cytogenetics (adjusted p = 0.697) and different from the survival curve
for patients in the intermediate IGP risk group (adjusted p = 0.028). C. Overall survival among patients with FLT3-ITD negative AML and high-risk mutations.
The overall survival curve for patients with FLT3-ITD negative (FLT3-ITD-) AML and co-occurring high-risk mutations (TET2, ASXL1 and/or PHF6) was not
significantly different from the survival curves for patients with unfavorable cytogenetics or patients with intermediate IGP risk (adjusted p = 0.111 and
Modified Prognostic Model in Younger Patients with AML
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Univariate and multivariate analyses. The correlations between clinical and genetic vari-
ables and prognosis were considered next. The only factor that was significant in the univariate
Cox regression analyses was the M-IGP classification (Table 5). Compared to patients in the
intermediate M-IGP risk group, patients with favorable M-IGP risk had significantly better
prognosis (HR = 0.47, 95% CI = 0.23–0.94, p = 0.034) and patients with unfavorable M-IGP
risk had significantly worse prognosis (HR = 2.07, 95% CI = 1.40–3.05, p<0.001). M-IGP pro-
file remained a significant prognostic factor in the multivariate model that controlled for clini-
cal factors and treatment site, and was the only significant factor in the reduced multivariate
model.
Discussion
Every AML diagnosis is accompanied by an assessment of prognosis, customarily based on the
clinical features of the patient as well as pre-treatment karyotype [1,19]. Prognostication not
only helps set accurate patient expectations, but also informs recommendations for post-remis-
sion therapy, including allogeneic SCT. Most experts recommend that patients with favorable
cytogenetics proceed with chemotherapy-based consolidation [9,18]. In contrast, patients with
unfavorable cytogenetics or other high-risk clinical features should undergo SCT in first remis-
sion, because of their poor chance of achieving cure with chemotherapy alone. An optimal
treatment course for patients with intermediate cytogenetics has not been defined, however
[18]. These patients have highly varied clinical outcomes, making it difficult to provide an
assessment of prognosis or informed recommendations for consolidation therapy.
Recently, a number of recurrent somatic mutations associated with AML have been shown
to be independently associated with prognosis [5,11,20–25]. The challenge is now to incorpo-
rate the prognostic information of these frequently co-occurring mutations with established
clinical and cytogenetic factors, in order to improve our ability to determine AML prognosis
and improve clinical care, particularly among patients with intermediate cytogenetics. The
European LeukemiaNet (ELN) was the first group to develop a prognostic model that
accounted for both cytogenetics and molecular markers. This model was validated in a large
European cohort [8], but only included mutations in three genes. Building on the ELN’s
approach, Patel et al. developed an integrated prognostic model with a wider range of molecu-
lar markers, using data from patients enrolled in a multicenter randomized controlled trial.
Despite the use of this model in clinical practice by some, it has not been validated in a second
cohort of patients.
p = 0.919, respectively). D. Overall survival among patients with FLT3-ITD positive AML and high-risk mutations. The overall survival curve for patients with
FLT3-ITD positive (FLT3-ITD+) AML and co-occurring high-risk mutations (trisomy 8, TET2 and/or DNMT3A) was similar to the survival curve for patients with
unfavorable cytogenetics (adjusted p = 0.793) and different from the survival curve for patients in the intermediate IGP risk group (adjusted p = 0.022).
doi:10.1371/journal.pone.0153016.g002
Table 4. Three-year overall survival by classification system.
3-year overall survival, % (95% CI)
Prognostic group Cytogenetic classiﬁcation Integrated genetic prognostic (IGP) model Modiﬁed IGP model
Favorable 77 (58–96) 69 (52–85) 69 (52–85)
Intermediate 34 (25–42) 33 (23–44) 36 (25–46)
Unfavorable 21 (4–37) 23 (12–34) 16 (5–27)
95% CI: 95% conﬁdence interval
doi:10.1371/journal.pone.0153016.t004
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We studied Patel et al.’s IGP model in a cohort of patients from two different institutions
who were not treated uniformly, reflecting variations seen in clinical practice. The proportions
of ECOG 1900 patients in each IGP risk group were similar to those of our study cohort [14].
Yet, the IGP model was not completely validated in our cohort: it did not consistently define
groups of AML patients with statistically significant differences in survival. We would therefore
not recommend its use as originally described in routine clinical practice. When we applied the
IGP model to our patient cohort, it did reclassify 50 of 137 patients with intermediate cytoge-
netics as having favorable or unfavorable mutational profiles, thus reducing the number of
patients with intermediate-risk AML from 70% to 44%. However, not all patients who were
reclassified to the favorable and unfavorable risk groups had survival outcomes that were truly
different from the intermediate risk group. It is crucial that the risk groups defined by a classifi-
cation model accurately describe survival outcomes and fully consider all treatment options,
including allogeneic stem cell transplant, which we are not able to assess due to lack of available
data. In our study, we created refined subgroups, defined by the M-IGP model, to provide a
Fig 3. Overall survival by modified IGP profile (n = 197). The overall survival curve for patients with
favorable M-IGP risk was significantly different from the survival curve for patients with unfavorable IGP risk
(adjusted p<0.001). There was no significant difference in survival curves between patients with favorable
M-IGP profiles and patients with intermediate M-IGP profiles (adjusted p = 0.178), or between patients with
unfavorable M-IGP profiles and patients with intermediate M-IGP profiles (adjusted p = 0.100).
doi:10.1371/journal.pone.0153016.g003
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comparison to the previous work by Patel et al. Further studies should investigate appropriate
management of these subgroups. It is also possible that a de novo approach to prognostication
would in fact define only two prognostic groups (favorable and unfavorable). Further studies
using an unbiased approach will address this question.
As shown, we assessed the survival curves for each IGP mutational subgroup to determine
where the IGP model was successful and whether it could be refined. We found that patients
who had FLT3-ITD negative NPM1mut/IDHmut AML had an OS curve that was significantly
different from that of the intermediate IGP risk group and similar to that of patients with
favorable cytogenetics, indicating that this molecular subgroup is truly a low-risk group. How-
ever, while survival among these patients was similar to survival among patients with favorable
cytogenetics in the first two years after diagnosis, it was closer to survival for the intermediate
IGP risk group after two years. This may suggest that while patients with NPM1mut/IDHmut
AML respond favorably to induction chemotherapy, they are more likely to relapse than
patients with core binding factor AML, leading to long-term outcomes similar to patients with
intermediate-risk AML. It is still not clear whether these patients should receive the same man-
agement as patients with favorable cytogenetics [26]. Future research should study long-term
survival among patients with this mutational profile.
Patients who had FLT3-ITD negative AML with co-occurring high-risk mutations (TET2,
ASXL1 and/or PHF6) had survival similar to patients with intermediate IGP risk AML and
therefore did not merit reclassification into an unfavorable risk group. To try to explain this
difference from Patel et al.’s results, it would be desirable to compare the clinical characteristics
of this group in the ECOG 1900 cohort and our study cohort; however, this information was
Table 5. Univariate andmultivariate Coxmodels for overall survival (n = 197).
Univariate model Multivariate model Reduced model
Hazard ratio (95% CI) P Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Age group
18–29 0.73 (0.40–1.32) 0.291 0.75 (0.36–1.58) 0.454 - - - - - -
30–39 0.79 (0.48–1.31) 0.357 0.77 (0.44–1.35) 0.360
40–49 1.05 (0.65–1.70) 0.855 1.34 (0.78–2.30) 0.291
50–60 - - - - - - - - - - - -
Sex
Female 1.12 (0.78–1.60) 0.547 0.97 (0.65–1.46) 0.882 - - - - - -
Male - - - - - - - - - - - -
M-IGP model
Favorable 0.47 (0.23–0.94) 0.034 0.68 (0.32–1.45) 0.318 0.47 (0.23–0.94) 0.034
Intermediate - - - - - - - - - - - - - - - - - -
Unfavorable 2.07 (1.40–3.05) <0.001 2.14 (1.38–3.48) 0.001 2.07 (1.40–3.05) <0.001
Site
Penn 1.08 (0.75–1.55) 0.697 0.93 (0.57–1.52) 0.770 - - - - - -
TCGA - - - - - - - - - - - -
White blood cell count 1.003 (1.00–1.01) 0.077 1.00 (0.998–1.01) 0.224 - - -
Hemoglobin 1.04 (0.93–1.16) 0.532 1.02 (0.88–1.17) 0.828 - - -
Platelets 1.001 (0.998–1.00) 0.485 1.00 (0.998–1.01) 0.300 - - -
Peripheral blasts 1.004 (0.998–1.01) 0.165 1.00 (0.99–1.01) 0.918 - - -
Bone marrow blasts 1.006 (0.998–1.01) 0.152 1.01 (0.99–1.02) 0.268 - - -
95% CI: 95% conﬁdence interval; M-IGP model: Modiﬁed integrated genetic prognostic model
doi:10.1371/journal.pone.0153016.t005
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not available for the ECOG 1900 cohort. In contrast, a third group of patients, those with
FLT3-ITD positive AML and co-occurring high-risk genetic changes (trisomy 8, TET2 and/or
DNMT3A) had an OS curve that was significantly different from that of the intermediate IGP
risk group and similar to that of patients with unfavorable cytogenetics. This result suggests
that this molecular subgroup is truly a high-risk group with an outcome similar to AML with
unfavorable cytogenetics. The genes included in this molecular subgroup should be incorpo-
rated into clinical testing outside of clinical trials, as these patients may benefit from SCT in
first remission, similar to patients with unfavorable cytogenetics.
Although we have not validated the overall IGP model, we do believe that two of the molec-
ular groups identified by Patel et al. deserve to be considered in patient management. We there-
fore refined the IGP model by reclassifying only two out of three mutational profiles. We
found that the intermediate M-IGP risk group included a larger proportion of patients (55%)
compared to the intermediate IGP risk group (44%), thus increasing the number of patients for
whom prognosis is less certain. However, this classification model ensures that patients seen in
clinical practice who meet criteria for each risk group are correctly classified. The M-IGP
model is thus more accurate when applied to our study cohort, but should be validated in other
cohorts in further studies. We propose that the IGP model should not be used indiscriminately
in all patient populations, as the performance of prognostic models may vary among patients
not included in the cohorts used to establish the models.
Several differences between our study and that conducted by Patel et al. [14] may explain
why the IGP model was not completely reproducible in our study cohort. First, the methodol-
ogy used to assess for mutations differed among the Penn, TCGA and ECOG 1900 cohorts.
The TCGA and Penn mutational analyses were performed using next generation sequencing
methodologies, which are quite analytically sensitive. The current level for clinical reporting at
Penn is 4% whereas Sanger sequencing, used by Patel et al., is considered to have a sensitivity
of only 20%. Second, our group of patients was not treated uniformly with high-dose anthracy-
cline-containing regimens, reflecting differences in clinical practice within and across institu-
tions. Variations in treatment may particularly impact patients with FLT3-ITD negative,
NPM1mut/IDHmut AML. Half of the patients in ECOG 1900 were randomized to high-dose
daunorubicin induction chemotherapy and recent studies suggest that high-dose chemother-
apy could significantly improve prognosis among patients with NPM1mutations [27]. Third,
the cytogenetic classification schema used by Patel et al. is different from the one used for our
cohort. We chose to use the MRC schema, as it was developed from a large cohort, is newer,
and is commonly used in clinical practice, both in the United States and in Europe [2]. Despite
these differences, we found that patients in the study cohort who had intermediate cytogenetics
and were FLT3-ITD negative NPM1mut/IDHmut had a very good prognosis, as predicted by
the IGP model. Patients who had intermediate cytogenetics and were FLT3-ITD positive with
co-occurring high-risk genetic changes had a very poor prognosis. This suggests that reclassifi-
cation of these two groups is valid and reproducible, regardless of differences in methodology
and clinical characteristics.
Our study has several limitations. First, it is limited by sample size, particularly when assess-
ing the association between individual mutations and OS. Second, we neither assessed the
impact of post-remission therapy and SCT on prognosis, nor included complete remission as
an endpoint, as this information was not available for TCGA patients and was not included by
Patel et al. as part of their published analysis. Third, in the years since Patel et al.’s paper was
published, increasing evidence has shown that mutations in CEBPA generally only affect prog-
nosis when they are biallelic [4,5]. We included both monoallelic and biallelic CEBPAmuta-
tions in our analysis, to emulate Patel et al.’s analysis. Finally, our gene panel did not include
MLL-PTD, a variant previously shown to be associated with poor prognosis [25,28,29].
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However, this mutation is only seen in 5–6% of patients with AML so it is unlikely that its
inclusion would have changed our overall conclusions [14,28].
In conclusion, we believe that while molecular markers have the potential to improve risk
stratification for patients60 years old with de novo AML, we should exercise caution when
developing integrated prognostic models to ensure that patients labeled as having favorable-,
intermediate-, or unfavorable-risk AML do indeed have different overall survival. Although we
did not completely validate the IGP model, we demonstrated that incorporation of six out of
nine mutations (FLT3-ITD, DNMT3A, TET2, NPM1, IDH1, IDH2) into clinical testing at diag-
nosis can be used to identify a group of lower risk and very high-risk patients with intermediate
cytogenetics. As these mutations are strong molecular determinants of survival, incorporation
of testing for them among younger patients with AML may help guide therapy. Given that 28%
of younger patients with AML have a three-year survival probability of 16%, further studies
should be undertaken to develop novel approaches to therapy for the highest-risk patients.
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S1 Fig. Overall survival by cytogenetic risk (n = 197). The survival curve for patients with
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ics (adjusted p = 0.141), or between patients with unfavorable cytogenetics and patients with
intermediate cytogenetics (adjusted p = 0.976).
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